Bicara Therapeutics (NASDAQ:BCAX) Announces Earnings Results, Misses Expectations By $0.08 EPS

Bicara Therapeutics (NASDAQ:BCAX) released its quarterly earnings data on Thursday. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.08), Zacks reports.

Bicara Therapeutics Stock Performance

BCAX opened at $13.40 on Friday. The company’s 50 day simple moving average is $13.04. Bicara Therapeutics has a one year low of $11.10 and a one year high of $28.09.

Analyst Upgrades and Downgrades

BCAX has been the subject of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.01 price target on shares of Bicara Therapeutics in a report on Thursday, March 13th. HC Wainwright raised their price objective on Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Finally, Wedbush reissued an “outperform” rating and set a $31.00 target price on shares of Bicara Therapeutics in a research report on Thursday. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $36.50.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.